Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines

Jeet Gandhi, Jianling Zhang, Yang Xie, Junichi Sou, Hisayuki Shigematsu, Wei Zhang, Hiromasa Yamamoto, Michael Peyton, Luc Girard, William W. Lockwood, Wan L. Lam, Marileila Varella-Garcia, John D. Minna, Adi F. Gazdar

Research output: Contribution to journalArticle

157 Citations (Scopus)

Abstract

Background: Deregulation of EGFR signaling is common in non-small cell lung cancers (NSCLC) and this finding led to the development of tyrosine kinase inhibitors (TKIs) that are highly effective in a subset of NSCLC. Mutations of EGFR (mEGFR) and copy number gains (CNGs) of EGFR (gEGFR) and HER2 (gHER2) have been reported to predict for TKI response. Mutations in KRAS (mKRAS) are associated with primary resistance to TKIs. Methodology/Principal Findings: We investigated the relationship between mutations, CNGs and response to TKIs in a large panel of NSCLC cell lines. Genes studied were EGFR, HER2, HER3 HER4, KRAS, BRAF and PIK3CA. Mutations were detected by sequencing, while CNGs were determined by quantitative PCR (qPCR), fluorescence in situ hybridization (FISH) and array comparative genomic hybridization (aCGH). IC50 values for the TKIs gefitinib (Iressa) and erlotinib (Tarceva) were determined by MTS assay. For any of the seven genes tested, mutations (39/77, 50.6%), copy number gains (50/77, 64.9%) or either (65/77, 84.4%) were frequent in NSCLC lines. Mutations of EGFR (13%) and KRAS (24.7%) were frequent, while they were less frequent for the other genes. The three techniques for determining CNG were well correlated, and qPCR data were used for further analyses. CNGs were relatively frequent for EGFR and KRAS in adenocarcinomas. While mutations were largely mutually exclusive, CNGs were not. EGFR and KRAS mutant lines frequently demonstrated mutant allele specific imbalance i.e. the mutant form was usually in great excess compared to the wild type form. On a molar basis, sensitivity to gefitinib and erlotinib were highly correlated. Multivariate analyses led to the following results: 1. mEGFR and gEGFR and gHER2 were independent factors related to gefitinib sensitivity, in descending order of importance. 2. mKRAS was associated with increased in vitro resistance to gefitinib. Conclusions/Significance: Our in vitro studies confirm and extend clinical observations and demonstrate the relative importance of both EGFR mutations and CNGs and HER2 CNGs in the sensitivity to TKIs.

Original languageEnglish
Article numbere4576
JournalPLoS One
Volume4
Issue number2
DOIs
Publication statusPublished - Feb 24 2009
Externally publishedYes

Fingerprint

erbB-1 Genes
lung neoplasms
Protein-Tyrosine Kinases
tyrosine
Lung Neoplasms
phosphotransferases (kinases)
Genes
Cells
cell lines
mutation
Cell Line
Mutation
genes
Non-Small Cell Lung Carcinoma
Deregulation
mutants
quantitative polymerase chain reaction
neoplasm cells
cells
Assays

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. / Gandhi, Jeet; Zhang, Jianling; Xie, Yang; Sou, Junichi; Shigematsu, Hisayuki; Zhang, Wei; Yamamoto, Hiromasa; Peyton, Michael; Girard, Luc; Lockwood, William W.; Lam, Wan L.; Varella-Garcia, Marileila; Minna, John D.; Gazdar, Adi F.

In: PLoS One, Vol. 4, No. 2, e4576, 24.02.2009.

Research output: Contribution to journalArticle

Gandhi, J, Zhang, J, Xie, Y, Sou, J, Shigematsu, H, Zhang, W, Yamamoto, H, Peyton, M, Girard, L, Lockwood, WW, Lam, WL, Varella-Garcia, M, Minna, JD & Gazdar, AF 2009, 'Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines', PLoS One, vol. 4, no. 2, e4576. https://doi.org/10.1371/journal.pone.0004576
Gandhi, Jeet ; Zhang, Jianling ; Xie, Yang ; Sou, Junichi ; Shigematsu, Hisayuki ; Zhang, Wei ; Yamamoto, Hiromasa ; Peyton, Michael ; Girard, Luc ; Lockwood, William W. ; Lam, Wan L. ; Varella-Garcia, Marileila ; Minna, John D. ; Gazdar, Adi F. / Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. In: PLoS One. 2009 ; Vol. 4, No. 2.
@article{8f947399045e464ebe00131d273bdd0d,
title = "Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines",
abstract = "Background: Deregulation of EGFR signaling is common in non-small cell lung cancers (NSCLC) and this finding led to the development of tyrosine kinase inhibitors (TKIs) that are highly effective in a subset of NSCLC. Mutations of EGFR (mEGFR) and copy number gains (CNGs) of EGFR (gEGFR) and HER2 (gHER2) have been reported to predict for TKI response. Mutations in KRAS (mKRAS) are associated with primary resistance to TKIs. Methodology/Principal Findings: We investigated the relationship between mutations, CNGs and response to TKIs in a large panel of NSCLC cell lines. Genes studied were EGFR, HER2, HER3 HER4, KRAS, BRAF and PIK3CA. Mutations were detected by sequencing, while CNGs were determined by quantitative PCR (qPCR), fluorescence in situ hybridization (FISH) and array comparative genomic hybridization (aCGH). IC50 values for the TKIs gefitinib (Iressa) and erlotinib (Tarceva) were determined by MTS assay. For any of the seven genes tested, mutations (39/77, 50.6{\%}), copy number gains (50/77, 64.9{\%}) or either (65/77, 84.4{\%}) were frequent in NSCLC lines. Mutations of EGFR (13{\%}) and KRAS (24.7{\%}) were frequent, while they were less frequent for the other genes. The three techniques for determining CNG were well correlated, and qPCR data were used for further analyses. CNGs were relatively frequent for EGFR and KRAS in adenocarcinomas. While mutations were largely mutually exclusive, CNGs were not. EGFR and KRAS mutant lines frequently demonstrated mutant allele specific imbalance i.e. the mutant form was usually in great excess compared to the wild type form. On a molar basis, sensitivity to gefitinib and erlotinib were highly correlated. Multivariate analyses led to the following results: 1. mEGFR and gEGFR and gHER2 were independent factors related to gefitinib sensitivity, in descending order of importance. 2. mKRAS was associated with increased in vitro resistance to gefitinib. Conclusions/Significance: Our in vitro studies confirm and extend clinical observations and demonstrate the relative importance of both EGFR mutations and CNGs and HER2 CNGs in the sensitivity to TKIs.",
author = "Jeet Gandhi and Jianling Zhang and Yang Xie and Junichi Sou and Hisayuki Shigematsu and Wei Zhang and Hiromasa Yamamoto and Michael Peyton and Luc Girard and Lockwood, {William W.} and Lam, {Wan L.} and Marileila Varella-Garcia and Minna, {John D.} and Gazdar, {Adi F.}",
year = "2009",
month = "2",
day = "24",
doi = "10.1371/journal.pone.0004576",
language = "English",
volume = "4",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "2",

}

TY - JOUR

T1 - Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines

AU - Gandhi, Jeet

AU - Zhang, Jianling

AU - Xie, Yang

AU - Sou, Junichi

AU - Shigematsu, Hisayuki

AU - Zhang, Wei

AU - Yamamoto, Hiromasa

AU - Peyton, Michael

AU - Girard, Luc

AU - Lockwood, William W.

AU - Lam, Wan L.

AU - Varella-Garcia, Marileila

AU - Minna, John D.

AU - Gazdar, Adi F.

PY - 2009/2/24

Y1 - 2009/2/24

N2 - Background: Deregulation of EGFR signaling is common in non-small cell lung cancers (NSCLC) and this finding led to the development of tyrosine kinase inhibitors (TKIs) that are highly effective in a subset of NSCLC. Mutations of EGFR (mEGFR) and copy number gains (CNGs) of EGFR (gEGFR) and HER2 (gHER2) have been reported to predict for TKI response. Mutations in KRAS (mKRAS) are associated with primary resistance to TKIs. Methodology/Principal Findings: We investigated the relationship between mutations, CNGs and response to TKIs in a large panel of NSCLC cell lines. Genes studied were EGFR, HER2, HER3 HER4, KRAS, BRAF and PIK3CA. Mutations were detected by sequencing, while CNGs were determined by quantitative PCR (qPCR), fluorescence in situ hybridization (FISH) and array comparative genomic hybridization (aCGH). IC50 values for the TKIs gefitinib (Iressa) and erlotinib (Tarceva) were determined by MTS assay. For any of the seven genes tested, mutations (39/77, 50.6%), copy number gains (50/77, 64.9%) or either (65/77, 84.4%) were frequent in NSCLC lines. Mutations of EGFR (13%) and KRAS (24.7%) were frequent, while they were less frequent for the other genes. The three techniques for determining CNG were well correlated, and qPCR data were used for further analyses. CNGs were relatively frequent for EGFR and KRAS in adenocarcinomas. While mutations were largely mutually exclusive, CNGs were not. EGFR and KRAS mutant lines frequently demonstrated mutant allele specific imbalance i.e. the mutant form was usually in great excess compared to the wild type form. On a molar basis, sensitivity to gefitinib and erlotinib were highly correlated. Multivariate analyses led to the following results: 1. mEGFR and gEGFR and gHER2 were independent factors related to gefitinib sensitivity, in descending order of importance. 2. mKRAS was associated with increased in vitro resistance to gefitinib. Conclusions/Significance: Our in vitro studies confirm and extend clinical observations and demonstrate the relative importance of both EGFR mutations and CNGs and HER2 CNGs in the sensitivity to TKIs.

AB - Background: Deregulation of EGFR signaling is common in non-small cell lung cancers (NSCLC) and this finding led to the development of tyrosine kinase inhibitors (TKIs) that are highly effective in a subset of NSCLC. Mutations of EGFR (mEGFR) and copy number gains (CNGs) of EGFR (gEGFR) and HER2 (gHER2) have been reported to predict for TKI response. Mutations in KRAS (mKRAS) are associated with primary resistance to TKIs. Methodology/Principal Findings: We investigated the relationship between mutations, CNGs and response to TKIs in a large panel of NSCLC cell lines. Genes studied were EGFR, HER2, HER3 HER4, KRAS, BRAF and PIK3CA. Mutations were detected by sequencing, while CNGs were determined by quantitative PCR (qPCR), fluorescence in situ hybridization (FISH) and array comparative genomic hybridization (aCGH). IC50 values for the TKIs gefitinib (Iressa) and erlotinib (Tarceva) were determined by MTS assay. For any of the seven genes tested, mutations (39/77, 50.6%), copy number gains (50/77, 64.9%) or either (65/77, 84.4%) were frequent in NSCLC lines. Mutations of EGFR (13%) and KRAS (24.7%) were frequent, while they were less frequent for the other genes. The three techniques for determining CNG were well correlated, and qPCR data were used for further analyses. CNGs were relatively frequent for EGFR and KRAS in adenocarcinomas. While mutations were largely mutually exclusive, CNGs were not. EGFR and KRAS mutant lines frequently demonstrated mutant allele specific imbalance i.e. the mutant form was usually in great excess compared to the wild type form. On a molar basis, sensitivity to gefitinib and erlotinib were highly correlated. Multivariate analyses led to the following results: 1. mEGFR and gEGFR and gHER2 were independent factors related to gefitinib sensitivity, in descending order of importance. 2. mKRAS was associated with increased in vitro resistance to gefitinib. Conclusions/Significance: Our in vitro studies confirm and extend clinical observations and demonstrate the relative importance of both EGFR mutations and CNGs and HER2 CNGs in the sensitivity to TKIs.

UR - http://www.scopus.com/inward/record.url?scp=84887212361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887212361&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0004576

DO - 10.1371/journal.pone.0004576

M3 - Article

AN - SCOPUS:84887212361

VL - 4

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 2

M1 - e4576

ER -